Nataliya Smirnova, Unsplash
Cognizant has expanded its relationship with biopharmaceutical company Gilead Sciences to leverage generative AI and enhance Gilead’s customer service experience.
Gilead utilizes innovative medicines to prevent and treat life-threatening diseases including HIV, viral hepatitis and cancer. Headquartered in Foster City, California, the company operates in more than 35 countries worldwide.
Under the agreement, Cognizant will manage Gilead’s global IT infrastructure, platforms, applications and advanced analytics, as well as lead initiatives designed to accelerate the organization’s digital transformation. The agreement includes renewal and expansion of Cognizant services for a total expected value of $800m over the next five years.
For over three years, the partnership has helped Gilead enable technologies for running business operations, launching new products and improving IT processes for efficient research, manufacturing and commercialization of its products.
The extended partnership will see Cognizant continue to support Gilead to enhance the internal and external client experience with IT infrastructure, security and platform services for its over 18,000 internal users. Cloud operations will be expanded for the biopharmaceutical firm, as its business applications continue to be modernized on cloud platforms, and Gilead will continue to receive support for its enterprise data and analytics platforms across all business functions.
Cognizant also anticipates leveraging Generative AI and AI automation with its Neuro IT service to help enhance Gilead’s customer service experience and assist the firm in driving greater manufacturing efficiencies.
Marc Berson, senior vice president and chief information officer, said: “Over the past three years, Cognizant has demonstrated quality delivery, adaptability and dedication to Gilead’s success.
“Through this collaboration, Cognizant has provided critical expertise to progress our digital transformation journey while enabling stable, secure operations. This has allowed us to advance research and commercialization of transformative treatments for some of the world’s most challenging diseases. We look forward to expanding this partnership to advance to the next phases of our capability roadmap.”
Surya Gummadi, executive vice president and president, Cognizant Americas, said: “We’re excited about this expanded partnership with Gilead, one of the pharmaceutical industry leaders in adapting advanced technologies to better deliver transformative treatments for patients worldwide.
“Working together our teams will be leveraging the latest technologies, from automation to cloud computing and generative AI, to help Gilead bring its products to market faster, more efficiently and with higher customer satisfaction.”
